tiprankstipranks
Processa Pharmaceuticals (PCSA)
NASDAQ:PCSA
US Market

Processa Pharmaceuticals (PCSA) Income Statement

108 Followers

Processa Pharmaceuticals Income Statement

Last quarter (Q4 2023), Processa Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Processa Pharmaceuticals's net income was $-2.38M. See Processa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 3.25M$ 11.46M$ 20.26M$ 12.13M$ 6.44M$ 3.94M
Operating Income
$ -3.25M$ -11.46M$ -27.53M$ -12.13M$ -6.44M$ -3.94M
Net Non Operating Interest Income Expense
$ 335.54K$ 335.54K$ 101.20K$ 11.63K$ -277.95K$ -25.11K
Other Income Expense
--$ 7.30M$ -163.77K$ -8.70M-
Pretax Income
$ -11.12M$ -11.12M$ -27.42M$ -11.96M$ -15.41M$ -3.96M
Tax Provision
--$ -7.45M$ -530.61K$ -1.00M$ -602.72K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -2.89M$ -11.10M$ -27.46M$ -11.43M$ -19.04M$ -3.86M
Basic EPS
$ -3.16$ -8.48$ -1.70$ -0.75$ -2.54$ -0.70
Diluted EPS
$ -3.16$ -8.48$ -1.70$ 0.00$ -2.54$ -0.70
Basic Average Shares
$ 52.47M$ 1.31M$ 16.11M$ 15.32M$ 7.50M$ 5.53M
Diluted Average Shares
$ 53.61M$ 1.31M$ 16.11M$ 15.32M$ 7.50M$ 5.53M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 3.25M$ 11.46M$ 20.26M$ 12.13M$ 6.44M$ 3.94M
Net Income From Continuing And Discontinued Operation
$ -11.10M$ -11.10M$ -27.42M$ -11.43M$ -14.41M$ -3.36M
Normalized Income
$ -1.90M$ -8.79M--$ -6.28M$ -3.36M
Interest Expense
----$ 281.12K$ 36.66K
EBIT
$ -11.21M$ -11.12M$ -27.42M$ -11.97M$ -15.13M$ -3.92M
EBITDA
$ -11.21M$ -11.12M$ -26.52M$ -11.18M$ -14.33M$ -3.12M
Currency in USD

Processa Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis